We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Harnessing Genetic Insights: Polygenic Risk Score Enhances Prediction of Peripheral Artery Disease and Limb Events

MedXY Editorial Team•Sep 6, 2026•Cardiology
polygenic risk scoremajor adverse limb eventsPeripheral Artery Disease

Highlight

  • A recently validated polygenic risk score (PRS) is independently associated with prevalent peripheral artery disease (PAD) and incidence of major adverse limb events (MALE) in cardiometabolic patients.
  • Each standard deviation increase in PRS confers a 15% higher odds of prevalent PAD and a 30% increased risk of MALE, comparable to established clinical risk factors.
  • Incorporating the PAD PRS with clinical variables modestly improves risk discrimination for MALE but may have limited immediate clinical utility.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Comparing Endovascular and Surgical Revascularization Outcomes in Claudication Due to Femoropopliteal Disease: Insights from Medicare-Linked DataThis study compares long-term outcomes of endovascular versus open bypass interventions for femoropopliteal disease in patients with claudication, finding similar rates of major adverse limb events and progression to critical limb ischemiaSep 17, 2026Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials: A Genotype-First Precision Prevention ApproachThis review synthesizes emerging evidence from the PROACT trials on genotype-first identification of subclinical coronary atherosclerosis using polygenic risk scores (PRS), highlighting feasibility, engagement, and high prevalence of silentSep 15, 2026Gene-Lifestyle Synergy in Diabetic Retinopathy DevelopmentThis study reveals how genetic risk for diabetic retinopathy can be significantly mitigated by healthy lifestyle choices, emphasizing universal behavioral interventions for prevention.Aug 23, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bempedoic Acid Significantly Reduces Limb and Cardiovascular Events in Statin-Intolerant Patients with Peripheral Artery Disease: Insights from the CLEAR Outcomes Trial
Bempedoic acid reduces the risk of major adverse limb and cardiovascular events in statin-intolerant patients with peripheral artery disease, illustrating its potential to enhance vascular risk management.
Aug 22, 2026
Declining Use But Persistent Readmissions: A National Analysis of Open Lower Extremity Revascularization OutcomesThis national study identifies key factors linked to 30-day nonelective readmissions after open lower extremity revascularization, highlighting stable readmission rates despite reduced procedure volume and the need for standardized dischargAug 19, 2026
Peripheral Artery Disease: Emerging Advances in Medical Therapy to Reduce Cardiovascular and Limb RisksThis article reviews recent advances in the medical management of peripheral artery disease, emphasizing comprehensive risk factor control, novel pharmacotherapies, and individualized approaches to improve cardiovascular and limb outcomes iJul 18, 2026